TITLE

$35.5M Arena Financing Will Restructure Debt, Stretch Cash

PUB. DATE
April 2011
SOURCE
Bioworld Week;4/4/2011, Vol. 19 Issue 14, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of Arena Pharmaceuticals Inc. to sell 12.15 million shares of its common stock and 12,150 shares of preferred stock to entities associated with Deerfield Management Co. LP along with gross proceeds of 35.5 million dollars.
ACCESSION #
60167017

 

Related Articles

  • Arena Raising $35.5M as PDUFA Date Looms.  // Bioworld Week;6/7/2010, Vol. 18 Issue 23, p4 

    The article reports on the 35.5 million U.S. dollars in shares agreed to be sold by Arena Pharmaceuticals Inc. to Deerfield Management to bolster cash as it seeks approval from the U.S. Food and Drug Administration (FDA) on the obesity compound lorcaserin.

  • Arena Gets $100M Loan as Lorcaserin Talks Continue.  // Bioworld Week;6/23/2009, Vol. 17 Issue 25, p1 

    The article offers information on the loan granted to Arena Pharmaceuticals Inc., San Diego, California, by Deerfield Management Co. It is stated that Arena will pay Deerfield a 2.25% transaction fee on the loan and 7.75% on the outstanding principal. Deerfield also has a two-year option to...

  • Arena Raising $35.5M in Stock Sale to Deerfield as PDUFA Date Looms. Hollingsworth, Catherine // BioWorld Today;6/4/2010, Vol. 21 Issue 107, p1 

    This article reports that Arena Pharmaceuticals has sold 35.5 million U.S. dollars worth of shares to Deerfield Management in a bid to bolster its cash as it seeks approval from the U.S. Food and Drug Administration for its obesity compound lorcaserin. Particular focus is given to the terms of...

  • $35.5M Arena Financing Will Restructure Debt, Stretch Cash. Shaffer, Catherine // BioWorld Today;3/30/2011, Vol. 22 Issue 61, p1 

    This article reports on the decision of Arena Pharmaceuticals Inc. to sell shares of common stock and shares of preferred stock to entities affiliated with Deerfield Management in 2011. Arena plans to use the proceeds to prepay a portion of loan principle owed to Deerfield. The company obtained...

  • Arena Public Offering Seeks $52M for Lorcaserin NDA Push.  // BioWorld Today;7/9/2009, Vol. 20 Issue 130, p1 

    The article reports on the $52.1 million public offering of shares by Arena Pharmaceuticals Inc. that is intended to keep it moving toward a new drug application (NDA) for its obesity drug lorcaserin. Arena will be offering 12.5 million shares, priced at $4.17 per share, which sent its shares...

  • KemPharm inks big deal. Moore, Adam // Corridor Business Journal;6/16/2014, Vol. 10 Issue 47, p1 

    The article reports on the $60 million financing deal of biopharmaceutical company KemPharm Inc. with New York-based Deerfield Management Co. for the development and approval of novel drugs that will prevent the growing epidemic of opioid abuse.

  • Financings roundup.  // Medical Device Daily;1/4/2012, Vol. 16 Issue 2, p2 

    The article reports on a debt facility agreement entered by iCAD with Deerfield Management in 2012.

  • KemPharm deal opens eyes.  // Corridor Business Journal;6/30/2014, Vol. 10 Issue 49, p16 

    The author reflects on the financing deal entered by Coralville, Iowa-based pharmaceutical company KemPharm Inc. from New York-based Deerfield Management Co. LP for the development of a drug that could combat opioid abuse.

  • Sermo secures funding for a global push. Arnold, Matthew // Medical Marketing & Media;May2013, Vol. 48 Issue 5, p11 

    The article reports on healthcare data developer WorldOne Interactive's efforts of securing $35 million from hedge fund firm Deerfield Management Co. LP for the U.S. presence of its acquired social network service provider Sermo Inc.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics